Cancer Chemotherapy and Pharmacology

, Volume 28, Issue 4, pp 298–301 | Cite as

The stability of mesna in beverages and syrup for oral administration

  • Marshall P. Goren
  • Beverly A. Lyman
  • Jackie T. Li
Original Articles Drug Stability, Ifosfamide, Oral Mesna


We evaluated the stability of the aqueous formulation of mesna during storage in syringes and after dilution in beverages and syrups. Measurements of the concentrations of mesna showed that the undiluted formulation was stable for at least 9 days in standard polypropylene syringes at 5°, 24°, and 35°C. There was no detectable oxidation of mesna to dimesna over the course of at least 1 week when mesna was diluted 1:2 and 1:5 in syrups and incubated at 24°C in capped tubes. Concentration changes were clinically negligible for 1:2, 1:10, and 1:100 dilutions of mesna in six carbonated drinks, two juices, and milk after incubation for 24 h at 5°C. Thus, the aqueous mesna formulation is stable when diluted and stored in a variety of beverages and syrups under conditions suitable for oral administration.


Cancer Research Syringe Oral Administration Polypropylene Concentration Change 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Araujo CE, Tessler J (1983) Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (mesna) to patients with inoperable lung cancer. Eur J Cancer Clin Oncol 19: 195–201Google Scholar
  2. 2.
    Brock N, Hilgard P, Pohl J, Ormstad K, Orrenius S (1984) Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols. J Cancer Res Clin Oncol 108: 87–97Google Scholar
  3. 3.
    Burkert H, Lucker PW, Wetzelsberger N, Breuel HP (1984) Bioavailability of orally administered mesna. Arzneimittelforschung 34: 1597–1600Google Scholar
  4. 4.
    Goren MP, Pratt CB, Meyer WM, Wright RK, Dodge RK, Viar MJ (1989) Mesna excretion and ifosfamide nephrotoxicity in children. Cancer Res 49: 7153–7157Google Scholar
  5. 5.
    James CA, Mant TG, Rogers HJ (1987) Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. Br J Clin Pharmacol 23: 561–568Google Scholar
  6. 6.
    Jones MS, Murrell RD, Shaw IC (1985) Excretion of sodium 2-mercaptoethanesulphonate mesna in the urine of volunteers after oral dosing. Eur J Cancer Clin Oncol 21: 553–555Google Scholar
  7. 7.
    Ormstad K, Orrenius S, Lastbom T, Uehara N, Pohl J, Stekar J, Brock N (1983) Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat. Cancer Res 43: 333–338Google Scholar
  8. 8.
    Radford JA, Margison JM, Swindell R, Lind MJ, Wilkinson PM, Thatcher N (1990) The stability of ifosfamide in aqueous solution and its suitability for continous 7-day infusion by ambulatory pump. Cancer Chemother Pharmacol 26: 144–146Google Scholar
  9. 9.
    Riddles PW, Blakely RL, Zerner B (1983) Reassessment of Ellman's reagent. Methods Enzymol 91: 49–60Google Scholar
  10. 10.
    Rowland CG, Bradford E, Adams P, Haines-Nutt RF, Jakobson K (1984) Infusion of ifosfamide plus mesna. Lancet II: 468Google Scholar
  11. 11.
    Shaw IC (1987) Mesna — a short review. Cancer Treat Rev 14: 67–86Google Scholar
  12. 12.
    Shaw IC, Weeks MS (1987) Excretion of disodium bis-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing. Eur J Cancer Clin Oncol 23: 933–935Google Scholar
  13. 13.
    Thannhauser TW, Konishi Y, Scherage HA (1984) Sensitive quantitative analysis of disulfide bonds in polypeptides and proteins. Anal Biochem 138: 181–188Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • Marshall P. Goren
    • 1
    • 2
  • Beverly A. Lyman
    • 3
  • Jackie T. Li
    • 1
  1. 1.Department of Pathology and Laboratory MedicineSt. Jude Children's Research HospitalMemphisUSA
  2. 2.Department of PathologyUniversity of Tennessee-MemphisUSA
  3. 3.Department of Clinical Laboratory SciencesUniversity of Tennessee-MemphisUSA

Personalised recommendations